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IMPORTANCE Multiple molecular signatures are available for managing estrogen receptor
(ER)–positive breast cancer but with little direct comparative information to guide the
patient’s choice.
OBJECTIVE To conduct a within-patient comparison of the prognostic value of 6multigene
signatures in womenwith early ER-positive breast cancer who received endocrine therapy for
5 years.
DESIGN, SETTING, AND PARTICIPANTS This retrospective biomarker analysis included 774
postmenopausal womenwith ER-positive ERBB2 (formerlyHER2)–negative breast cancer.
This analysis was performed as a preplanned secondary study of data from the Anastrozole or
Tamoxifen Alone or Combined randomized clinical trial comparing 5-year treatment with
anastrozole vs tamoxifen with 10-year follow-up data. The signatures included the Oncotype
Dx recurrence score, PAM50-based Prosigna risk of recurrence (ROR), Breast Cancer Index
(BCI), EndoPredict (EPclin), Clinical Treatment Score, and 4-marker immunohistochemical
score. Data were collected from January 2009, through April 2015.
MAIN OUTCOMES ANDMEASURES The primary objective was to compare the prognostic value
of these signatures in addition to the Clinical Treatment Score (nodal status, tumor size,
grade, age, and endocrine treatment) for distant recurrence for 0 to 10 years and 5 to 10
years after diagnosis. Likelihood ratio (LR) statistics were used with the χ2 test and C indexes
to assess the prognostic value of each signature.
RESULTS In this study of 774 postmenopausal womenwith ER-positive, ERBB2-negative
disease (mean [SD] age, 64.1 [8.1] years), 591 (mean [SD] age, 63.4 [7.9] years) had
node-negative disease. The signatures providing themost prognostic information were the
ROR (hazard ratio [HR], 2.56; 95% CI, 1.96-3.35), followed by the BCI (HR, 2.46; 95% CI,
1.88-3.23) and EPclin (HR, 2.14; 95% CI, 1.71-2.68). Each provided significantly more
information than the Clinical Treatment Score (HR, 1.99; 95% CI, 1.58-2.50), the recurrence
score (HR, 1.69; 95% CI, 1.40-2.03), and the 4-marker immunohistochemical score (HR, 1.95;
95% CI, 1.55-2.45). Substantially less information was provided by all 6 molecular tests for the
183 patients with 1 to 3 positive nodes, but the BCI (ΔLR χ2 = 9.2) and EPclin (ΔLR χ2 = 7.4)
providedmore additional prognostic information than the other signatures.
CONCLUSIONS AND RELEVANCE For womenwith node-negative disease, the ROR, BCI, and
EPclin were significantly more prognostic for overall and late distant recurrence. For women
with 1 to 3 positive nodes, limited independent information was available from any test.
These data might help oncologists and patients to choose themost appropriate test when
considering chemotherapy use and/or extended endocrine therapy.
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A lmost all women with estrogen receptor (ER)–positiveprimary breast cancer are offered adjuvant endocrinetherapy, and a highly relevant clinical question is who
remains at high risk for distant recurrence despite completion
ofprimaryadjuvanttherapy.Multigeneexpressionprofileshave
significantly increased our ability to estimate distant recur-
rence in ER-positive breast cancer after surgery and endocrine
treatment.1 These signatures areused in combinationwithdif-
ferent clinical characteristics to aid the selectionofpatients for
whom chemotherapymay be appropriate based on prognosis.
Several of these signatures are commercially available, includ-
ing the Oncotype Dx recurrence score (RS) (Genomic Health),
PAM50-based Prosigna risk of recurrence (ROR) (NanoString),
Breast Cancer Index (BCI) (bioTheranostics), EndoPredict
(EPclin) (MyriadGenetics),andMammaPrintNetherlandKanker
Institute 70-gene signature (AgendiaBV), are endorsedby sev-
eral guidelines2-5 and are routinely used by clinicians.
TheTranslationalStudyofAnastrozoleorTamoxifenAlone
or Combined (TransATAC) cohort was previously used to de-
velop 2 prognostic algorithms, the Clinical Treatment Score
(CTS), which includes clinicopathologic information, and the
4-marker immunohistochemical score (IHC4), which com-
bines prognostic information of 4 widely used IHCmarkers.6
The following 4 gene expression–based signatures were also
evaluated in the TransATAC cohort: the RS,6 ROR,7 BCI,8 and
EPclin.9 The RS and BCI include only molecular information
in their signatures, whereas the ROR (tumor size) and EPclin
(tumor size and number of positive nodes) integrate clinical
information. All these signatures significantly estimated the
risk of distant recurrence, particularly in women with node-
negative disease, butwith a varying amount of prognostic in-
formation for late distant recurrence (5-10 years). An impor-
tant area of research remains to accurately estimate the risk
of late distant recurrence inwomenwith ER-positive disease,
because more than 50% of recurrences occur after 5 years of
endocrinetreatment.Geneexpression–basedsignaturesshould
showan improvement inprognosticationwhencomparedwith
standard clinical measures.8,10,11
Toour knowledge, nodirect andcomprehensive compari-
son of multigene signatures has been performed in the same
patient population with long-term follow-up data. We com-
pared the prognostic performance of 6 signatures for distant
recurrence in the 10-year period after diagnosis to assess the
potential valueof adding chemotherapyvs endocrine therapy
alone and for late distant recurrence in years 5 to 10 to inves-
tigate the potential value of extended adjuvant endocrine
therapy. Furthermore, the comparison was performed sepa-
rately for women with node-negative disease and those with
1 to 3 positive nodes because the most significant prognostic
clinical indicator for early-stage breast cancer is the presence
or absence of lymph node involvement.
Methods
Study Design and Patients
In this preplanned comparative analysis, tumor blocks from
the TransATAC studywere used from patients with hormone
receptor–positiveearly-stagebreast cancer treatedwith5years
of tamoxifen or anastrozole in the ATAC randomized clinical
trial.12Microdissectionof the tumors andRNAextractionwere
performedbyGenomicHealth, Inc, and residualRNAwaspro-
vided to collaborators forRNAexpressionprofiling.Datawere
collected fromJanuary2009, throughApril 2015.Womenwere
excluded fromtheanalysis if they receivedchemotherapy, did
not haveER-positive disease, received the combination treat-
ment (ie, anastrozole plus tamoxifen), or had 4 or more posi-
tive lymph nodes. This study was approved by the South-
EastLondonResearchEthicsCommittee.All patientsprovided
written informed consent for their tissue to be used in trans-
lational research.
Procedures
TheCTSand IHC4weredeveloped in theTransATACstudyand
havebeendescribed indetail previously.6 Inbrief, theCTScon-
tains information onnodal status, grade, tumor size, age, and
treatment (tamoxifen vs anastrozole). The IHC4 combines 4
commonly used IHCmarkers, including ER, progesterone re-
ceptor,Ki67, andERBB2 (formerlyknownasHER2 [RefSeqNM
_001005862.2]). The commercial signatures arebasedonRNA
expression profiling and were performed according to speci-
ficationsby4ofus (R.K.,S.F.,C.S., andF.L.B.)whowereblinded
to clinical outcome data. The RS13 is a 21-gene signature that
was developed for patients with ER-positive, node-negative
breast cancer. The RS risk groups were determined for pa-
tients with node-negative cancer as previously described,13
using predefined cutoffs of less than 18, 18 to 31, and greater
than31 todetermine low-, intermediate-, andhigh-riskgroups,
respectively. The RS-pathology-clinical (RSPC) score was cal-
culated using the website tool for patients with node-
negative breast cancer.14 The BCI15,16 combines the 2-gene
HOXB13:IL17BR ratiowith themolecular grade index consist-
ing of 5 proliferation genes in a linear model and was devel-
oped in postmenopausal patients with ER-positive, lymph
node–negative breast cancer.8 Cutoff points for the BCI were
determined in a population with node-negative disease (low
risk <5.0825; high risk >6.5025).17 The ROR7 incorporates 46
genes and was developed in premenopausal and postmeno-
pausalwomen treatedwithout anyadjuvant systemic therapy
Key Points
Question What is the comparative performance of prognostic
multigene signatures for estimation and risk stratification of
overall and late distant recurrence in estrogen receptor–positive
ERBB2-negative breast cancer?
Findings In this biomarker analysis of data from a randomized
clinical trial, a combination of multigene expression tests with
clinical information was associated with improved prognostic
value for distant recurrences and risk stratification specifically in
womenwith node-positive disease. Differences in the prognostic
value for late distant recurrence were observed.
Meaning The combination of clinical andmolecular information
may enhance the prognostic value for distant recurrence and risk
stratification in estrogen receptor–positive, ERBB2-negative breast
cancer, particularly for womenwith node-positive disease.
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and includes information on tumor size. The TransATAC co-
hort was used to determine the cutoff points of the ROR for
risk stratification in patients with node-negative and node-
positivedisease separately.Theycorrespondapproximately to
a point estimate of as much as a 10% distant recurrence rate
for lowriskandmore thana20%rate forhigh riskafter 10years
of follow-up.18 The EPclin was developed in premenopausal
and postmenopausal tamoxifen-treated patients with ER-
positive,ERBB2-negativebreast cancer. It incorporates theex-
pressionof 12 genesplus informationon tumor size andnodal
status.19 Apredefined cutoff point (3.3, basedonmethodsde-
scribedbyFilipits et al19)wasused for risk stratification,which
corresponds to a 10% distant recurrence risk at 10 years.
Statistical Analysis
Theprimaryendpointwas the time todistant recurrence.Dis-
tant recurrence was defined as metastatic disease, excluding
contralateral disease, and locoregional and ipsilateral recur-
rences. Death before distant recurrence was treated as a cen-
soring event. We defined the following 2 primary analysis
populations:patientswithER-positive,ERBB2-negative,node-
negativebreast cancer, andpatientswithER-positive,ERBB2-
negative breast cancer with 1 to 3 positive lymph nodes. The
primary objective was the comparison of prognostic signa-
tures in patients with node-negative and node-positive dis-
ease separately for overall (0-10years) and late (5-10years) fol-
low-up periods.
Weassessedoverall distant recurrence in the first 10years
after diagnosis (n = 774) and latedistant recurrencewithin the
subset of patientswho remained free of distant recurrence for
the first 5 years after diagnosis (n = 689). Partial likelihood ra-
tio (LR) tests based on Cox proportional hazards regression
modelswereused to test theprognostic informationof all sig-
natures. The amount of prognostic information provided by
each signature alone was assessed by C indexes. Further-
more, partial LR χ2 valueswith a 2-sided 5%significance level
(LR χ2 = 3.84) are also presented. The improvement in dis-
tant recurrence prognostication of each signature compared
with clinical andpathologic variables (CTS)was quantified by
the increase in the LR χ2 value (ΔLR χ2; 2-sided 5% signifi-
cance level). Predefined cutoffs were used to determine risk
stratification for the 4 commercially available signatures.
Kaplan-Meier curves were used to estimate the mean risk of
distant recurrenceafter 10yearsof follow-up inpredefined risk
groups. To compare the prognostic performance of all signa-
tures, continuous scores were normalized to have unit vari-
ance, and thehazard ratios (HRs) andassociated95%CIswere
estimated from Cox proportional hazards regressionmodels.
All statistical analyseswere 2-sided, and aPvalue of less than
.05 was regarded as significant. All analyses were performed
with Stata software (version 13.1; StataCorp).
Results
A total of 774 postmenopausal women with ER-positive,
ERBB2-negative disease for whom all signatures were avail-
able were included in this analysis (mean [SD] age, 64.1 [8.1]
years) (eFigure 1 in the Supplement). Five hundred ninety-
onewomen had node-negative disease, with amean (SD) age
of 63.4 (7.9) years andamean (SD) tumor size of 17.6 (8.5)mm.
A total of 58distant recurrences (9.8%)were recorded for this
population, with approximately half of distant recurrences
(n = 34) occurring in the late follow-up period (eTable 1 in the
Supplement). In contrast, women with 1 to 3 positive nodes
(n = 183) were significantly older (mean [SD] age, 66.4 [8.3]
years) andhadsignificantly larger tumors (mean [SD] size, 24.2
[12.2] mm) than those with negative nodes (eTable 1 in the
Supplement). Forty distant recurrences were recorded dur-
ing 10years of follow-up,with 21 of themoccurring 5 years af-
ter the diagnosis. Results of the prognostic performance of all
6 signatures for theoverallpopulation (withnode-negativeand
node-positive disease combined) and C indexes are shown in
eTable 2 in the Supplement.
Recurrence During Years 0 to 10
PopulationWith Node-Negative Disease
All 6 signatures provided a statistically significant prognostic
value for distant recurrence during years 0 to 10; all HRs and
C indexes are shown in Table 1. The ROR (HR, 2.56; 95% CI,
1.96-3.35), BCI (HR, 2.46; 95% CI, 1.88-3.23), and EPclin (HR,
2.14; 95% CI, 1.71-2.68) proved to be statistically more prog-
nostic than theother signatures in thispatientpopulation.The
CTS (HR, 1.99; 95%CI, 1.58-2.50) and IHC4 (HR, 1.95; 95%CI,
1.55-2.45) provided similar amounts of prognostic informa-
tion in this period (Table 1 and eFigure 2 in the Supplement).
All signatures provided independent prognostic information
beyond theCTS forwomenwithnode-negativedisease; inpar-
Table 1. Univariate HRs and C Indexes for All Prognostic Signatures According to Nodal Status
During Years 0 to 10
Gene
Signature
Patient Group
Node-Negative Disease
(n = 591)
Node-Positive Disease
(n = 227)
HR (95% CI)a C Index (95% CI) HR (95% CI)a C Index (95% CI)
CTS 1.99 (1.58-2.50) 0.721 (0.668-0.774) 1.63 (1.20-2.21) 0.640 (0.554-0.726)
IHC4 1.95 (1.55-2.45) 0.725 (0.665-0.785) 1.33 (0.99-1.78) 0.601 (0.511-0.690)
RS 1.69 (1.40-2.03) 0.667 (0.585-0.750) 1.39 (1.05-1.85) 0.603 (0.513-0.693)
BCI 2.46 (1.88-3.23) 0.762 (0.704-0.820) 1.67 (1.21-2.29) 0.652 (0.566-0.739)
ROR 2.56 (1.96-3.35) 0.764 (0.707-0.821) 1.58 (1.16-2.15) 0.636 (0.552-0.719)
EPclin 2.14 (1.71-2.68) 0.765 (0.716-0.814) 1.69 (1.29-2.22) 0.671 (0.590-0.752)
Abbreviations: BCI, Breast Cancer
Index; CTS, Clinical Treatment Score;
EPclin, EndoPredict clinical score;
HR, hazard ratio; IHC4, 4-gene
immunohistochemical score;
ROR, risk of recurrence;
RS, recurrence score.
a All HRs indicate a change in 1 SD.
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ticular, the BCI and ROR provided the most prognostic value
(eFigure 2 in the Supplement).
We determined 10-year distant recurrence risks for the
4 commercially available multigene signatures using pre-
defined cutoffs (Figure 1 and Table 2). All 4 signatures identi-
fied a large proportion of women who were at low risk of de-
veloping a distant recurrence (<10%) after 10 years of follow-
up.TheEPclin signaturehasonly2 riskgroupsandcategorized
Figure 1. Kaplan-Meier Curves for Recurrence During Years 0 to 10
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Includes 591 patients with node-negative and 183 patients with node-positive
disease. Data are stratified by signature and nodal status. Gene signatures
include the Oncotype Dx recurrence score (Genomic Health), PAM50-based
Prosigna risk of recurrence score (NanoString), Breast Cancer Index
(bioTheranostics), and EPclin (EndoPredict clinical score [Myriad Genetics]).
Cutoffs for risk of recurrence score were trained separately in patients with
node-negative and node-positive disease in the Translational Study of
Anastrozole or Tamoxifen Alone or Combined cohort.
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429 women (72.6%) into the low-risk group, of whom 27 de-
veloped a distant recurrence (10-year distant recurrence risk,
6.6%; 95% CI, 4.5%-9.7%) (Figure 1 and Table 2). Only 61 pa-
tients (10.3%)were categorized into thehigh-risk groupby the
RS,andtheyhada10-yeardistant recurrenceriskof27.2%(95%
CI, 17.3%-41.2%). The EPclin, BCI, and ROR identified larger
proportions of women as having a high risk with 10-year dis-
tant recurrence risks of 22.1% (95% CI, 16.2%-29.8%), 27.3%
(95%CI, 18.7%-38.8%), and 32.4% (95%CI, 23.4%-43.8%), re-
spectively (Figure 1 and Table 2). For 507 women, informa-
tion for the RSPC score was also available, and the incorpora-
tionof clinical variables into theRSsubstantially improved the
prognostic performance fordistant recurrence comparedwith
the molecular RS alone.
PopulationWith 1 to 3 Positive Nodes
TheCTS (HR, 1.63; 95CI, 1.20-2.21), BCI (HR, 1.67; 95%CI, 1.21-
2.29), ROR (HR, 1.58; 95% CI, 1.16-2.15), and EPclin (HR, 1.69;
95% CI, 1.29-2.22) provided significant prognostic informa-
tion in this patient population (Table 1). The prognostic per-
formance of all signatures, although significant, was weaker
than for node-negative disease, as evidenced by the smaller
HRs andC indexes in this patient group.The IHC4didnotpro-
vide prognostic value for distant recurrence. Apart from the
IHC4, all signatures provided independent prognostic infor-
mation, with the BCI (ΔLR χ2 = 9.2) and EPclin (ΔLR χ2 = 7.4)
showing the largest improvements beyond the CTS (eFigure
2 in the Supplement).
Risk group stratification is shown in Figure 1 and Table 2.
TheROR identifieda small groupofwomen (n = 15) as lowrisk,
of whom none developed a distant recurrence at 10 years
(Figure 1 and Table 2). The EPclin categorized 43 women
(23.5%) into the low-risk group, with a 5.6% (95% CI, 1.4%-
20.9%) risk of distant recurrence at 10 years. Both signatures
identified most women as high risk with a mean 10-year dis-
tant recurrence risk ofmore than 30%. In contrast, a highpro-
portionofwomenwerecategorized intothe low-riskgroupwith
a high risk of distant recurrence at 10 years by the BCI (15.5%;
Table 2. Risk of Distant Recurrence AmongWomenWith Node-Negative and Node-Positive Disease
by Gene Signaturea
Gene Signature
Node-Negative Disease Node-Positive Disease
No. (%) 10-y Risk, % (95%CI) No. (%) 10-y Risk, % (95% CI)
Years 0-10
BCI
Low 365 (61.8) 3.9 (2.3-6.7) 95 (51.9) 15.5 (9.3-25.3)
Intermediate 143 (24.2) 19.3 (13.3-27.6) 60 (32.8) 32.0 (21.1-46.6)
High 83 (14.0) 27.3 (18-7-38.8) 28 (15.3) 41.4 (24.3-64.1)
RS
Low 374 (63.3) 5.9 (3.8-9.1) 105 (57.4) 19.4 (12.5-29.5)
Intermediate 156 (26.4) 16.7 (11.5-24.0) 58 (31.7) 29.1 (18.9-43.1)
High 61 (10.3) 27.2 (17.3-41.2) 20 (10.9) 38.0 (20.0-64.1)
ROR
Low 318 (53.8) 3.0 (1.6-5.8) 15 (8.2) 0
Intermediate 178 (30.1) 14.1 (9.4-20.8) 58 (31.7) 20.7 (12.0-34.4)
High 95 (16.1) 32.4 (23.4-43.8) 110 (60.1) 30.7 (22.2-41.3)
EPclin
Low 429 (72.6) 6.6 (4.5-9.7) 43 (23.5) 5.6 (1.4-20.9)
High 162 (27.4) 22.1 (16.2-29.8) 140 (76.5) 30.3 (23.0-39.3)
Years 5-10a
BCI
Low 340 (63.6) 2.6 (1.3-5.0) 84 (54.6) 9.5 (8.3-23.9)
Intermediate 126 (23.6) 14.4 (9.0-22.6) 50 (32.5) 14.3 (8.3-23.9)
High 69 (12.8) 15.9%(8.9-27.6) 20 (13.0) 36.5 (20.4-59.6)
RS
Low 351 (65.6) 4.8 (2.9-7.9) 94 (61.0) 17.9 (11.5-27.3)
Intermediate 134 (25.1) 9.6 (5.6-16.3) 45 (29.2) 19.5 (10.9-33.5)
High 50 (9.3) 16.1 (8.0-30.8) 15 (9.7) 27.5 (11.2-57.9)
ROR
Low 292 (54.6) 1.4 (0.5-3.8) 15 (9.7) 0
Intermediate 165 (30.8) 10.0 (6.0-16.5) 51 (33.1) 13.0 (6.1-26.7)
High 78 (14.6) 23.2 (14.9-35.2) 88 (57.1) 25.0 (17.5-35.0)
EPclin
Low 393 (73.5) 4.3 (2.6-7.1) 40 (26.0) 3.3 (0.5-21.4)
High 142 (26.5) 14.6 (9.6-22.0) 114 (74.0) 23.6 (17.0-32.1)
Abbreviations: BCI, Breast Cancer
Index; EPclin, EndoPredict clinical
score; HR, hazard ratio; IHC4, 4-gene
5 immunohistochemical score;
ROR, risk of recurrence;
RS, recurrence score.
a Percentages have been rounded
andmay not total 100.
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95% CI, 9.3%-25.3%) and the RS (19.4%; 95% CI, 12.5%-
29.5%) (Figure 1 and Table 2).
Recurrence During Years 5 to 10
PopulationWith Node-Negative Disease
To assess the prognostic power of each signature for late dis-
tant recurrence, 535 womenwhowere alive and without dis-
tant recurrence after 5 years of follow-up were included. The
HRs and C indexes are shown in Table 3. The ROR (HR, 2.77;
95% CI, 1.93-3.96), BCI (HR, 2.30; 95% CI, 1.61-3.30), and
EPclin (HR, 2.19; 95%CI, 1.62-2.97) provided significant prog-
nostic value for late distant recurrence (Table 3 and eFigure 3
in theSupplement) and substantiallymore than theCTSalone
(HR, 1.95; 95% CI, 1.43-2.65). The IHC4 and RS did not pro-
vide significant prognostic value for late distant recurrence
whenaddedtoCTS(eFigure3 in theSupplement).TheBCI (ΔLR
χ2 = 11.2), EPclin (ΔLR χ2 = 10.3), and, in particular, ROR (ΔLR
χ2 = 18.4) provided significant independent prognostic infor-
mation for late distant recurrence beyond the CTS (eFigure 3
in the Supplement). The RSPC score provided twice as much
prognostic information for late distant recurrence compared
with the RS alone in the univariate analysis but no prognostic
value for late distant recurrence additional to CTS.
All 4 signatures categorized most of the women into the
low-risk group, who had a low mean distant recurrence risk
in years 5 to 10 of less than 5% (Figure 2 and Table 2). The
EPclincategorized142patients (26.5%) intothehigh-riskgroup,
which had the lowest 10-year distant recurrence risk of 14.6%
(95% CI, 9.6%-22.0%). In contrast, the ROR identified 78
women (14.6%) as high risk, and they had the highest 10-year
risk of distant recurrence of any test (23.2%; 95% CI, 14.9%-
35.2%) (Figure 2 and Table 2).
PopulationWith 1 to 3 Positive Nodes
We included 154 women who were alive without distant re-
currencewithin the first 5yearsof follow-up (Table 3 andeFig-
ure 3 in the Supplement). The EPclin provided themost prog-
nostic value for late distant recurrence (HR, 1.87; 95%CI, 1.27-
2.76), followed by the ROR (HR, 1.65; 95% CI, 1.08-2.51) and
BCI (HR, 1.60; 95% CI, 1.04-2.47) (Table 3). The IHC4 and RS
did not provide prognostic information for late distant recur-
rence univariately or in addition to the CTS (eFigure 3 in the
Supplement). TheEPclin (ΔLRχ2 = 6.1) andBCI (ΔLRχ2 = 4.6)
added significant but limited independent prognostic infor-
mation to the CTS (eFigure 3 in the Supplement).
Good risk stratification in this patient group was ob-
served for theBCI, ROR, andEPclin (Figure 2 andTable 2). The
ROR categorized 15 women (9.7%) into the low-risk group, of
whom none developed a late distant recurrence. The EPclin
identified a larger proportion of women as low risk (40
[26.0%]), of whom only 1 developed a distant recurrence by
year 10. No clear risk stratification was observed for the RS
(Figure 2 and Table 2).
Discussion
Multigene signatures havebecome increasingly important for
the prognostic evaluation of ER-positive, ERBB2-negative
breast cancer.6,20,21Hereinwe compared theprognostic value
of 6 signatures for distant recurrence in the TransATAC co-
hort. During years 0 to 10, all signatures provided significant
prognostic information for women with node-negative dis-
ease inadditiontoclinicalvariables.Forwomenwith1 to3posi-
tive nodes, the independent prognostic strength of the inves-
tigated signatures was weaker. Although fewer patients had
node-positive thannode-negativedisease, thenumber of dis-
tant recurrenceswas similar and thusprovided similar power.
For late distant recurrence, the BCI, ROR, and EPclin pro-
vided independent prognostic information for women with
node-negative disease and those with 1 to 3 positive nodes.
Wepreviouslypublishedtheresultsof the individualevalu-
ationsof the4 commercial signatures and showed that all pro-
vide significant and similar prognostic informationduring the
first5yearsafterdiagnosis.6-9 In this study,werevealedthat the
difference inprognostic performancebetweensignaturesdur-
ing 10years of follow-upmayhavebeen largely attributable to
theirdifferential ability toestimatedistant recurrence from5to
10years.Thus, theBCI,8,22ROR,23 andEPclin9,10mayhavemo-
lecularcomponents intheir signatures thataremorespecifically
prognostic for late recurrencecomparedwith the IHC4and the
RS. Of importance, combined genomic and clinical models
showedenhancedprognostic performanceparticularly forpa-
tientswith 1 to3positive lymphnodesandthusmaybe thepre-
ferredapproachfor thedecision-makingprocess for thispatient
group.Furthermore, theRSPCscoreprovidedsignificantlymore
prognostic value for distant recurrence in patientswith node-
negative disease than did themolecular RS alone.
In the adjuvant setting, the need for chemotherapy or ex-
tended endocrine therapy (for late recurrence) is an impor-
Table 3. Univariate HRs and C Indexes for All Prognostic Signatures According to Nodal Status
During Years 5 to 10
Gene
Signature
Patient Group
Node-Negative Disease
(n = 535)
Node-Positive Disease
(n = 154)
HR (95% CI)a C Index (95% CI) HR (95% CI)a C Index (95% CI)
CTS 1.95 (1.43-2.65) 0.721 (0.654-0.788) 1.61 (1.05-2.47) 0.644 (0.534-0.753)
IHC4 1.59 (1.16-2.16) 0.660 (0.576-0.745) 1.20 (0.79-1.81) 0.579 (0.460-0.697)
RS 1.46 (1.09-1.96) 0.585 (0.467-0.702) 1.24 (0.81-1.90) 0.555 (0.418-0.693)
BCI 2.30 (1.61-3.30) 0.749 (0.668-0.830) 1.60 (1.04-2.47) 0.633 (0.514-0.751)
ROR 2.77 (1.93-3.96) 0.789 (0.724-0.854) 1.65 (1.08-2.51) 0.643 (0.528-0.758)
EPclin 2.19 (1.62-2.97) 0.768 (0.701-0.835) 1.87 (1.27-2.76) 0.697 (0.594-0.799)
Abbreviations: BCI, Breast Cancer
Index; CTS, Clinical Treatment Score;
EPclin, EndoPredict clinical score;
HR, hazard ratio; IHC4, 4-gene
immunohistochemical score;
ROR, risk of recurrence;
RS, recurrence score.
a All HRs indicate a change in 1 SD.
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tant clinical decision. We used predefined cutoffs to deter-
mine the 10-year distant recurrence risk for the commercial
scores during years 0 to 10 (chemotherapy) and 5 to 10 (ex-
tended endocrine therapy). For node-negative disease, most
of the womenwere categorized into the low-risk group by all
4 signatures, andwomen had amean risk of less than 7%, for
whom chemotherapy might not be indicated. The 2 signa-
tures that contain clinical variables (ROR and EPclin) identi-
Figure 2. Kaplan-Meier Curves for Recurrence During Years 5 to 10
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Includes 535 patients with node-negative and 154 with node-positive disease.
Data are stratified by signature and nodal status. Gene signatures include the
Oncotype Dx recurrence score (Genomic Health), PAM50-based Prosigna risk of
recurrence score (NanoString), Breast Cancer Index (bioTheranostics), and
EPclin (EndoPredict clinical score [Myriad Genetics]). Cutoffs for risk of
recurrence score were trained separately in patients with node-negative and
node-positive disease in the Translational Study of Anastrozole or Tamoxifen
Alone or Combined cohort.
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fied a sizeable group ofwomenwith 1 to 3 positive nodeswho
hadavery lowriskofdistant recurrenceat 10years (mean risk,
<6%), suggesting that chemotherapy would be of very lim-
ited benefit in these women.
None of the signatures were specifically developed to es-
timate late distant recurrences. However, the BCI, ROR, and
EPclin demonstrated accurate prognostic value for these late
events inouranalysis.Wolmarkandcolleagues24 reported that
theRSwas significantly prognostic for late distant recurrence
but only in patients with high ESR1 levels. However, we did
not observe an association between high ESR1 levels and late
distant recurrencewith theRS inourdataset.A fewstudies25-28
have investigated a series of extendedendocrine therapywith
aromatase inhibitors toaddress thequestionof the ideal length
ofextendedtreatment.TheMA17.R trial25 showedthat 10years
of letrozole therapy resulted in significantly higher rates of
disease-free survival comparedwith placebo. In the National
SurgicalAdjuvantBreast andBowelProject (NSABP-B42),26ex-
tended adjuvant aromatase inhibition after sequential endo-
crine therapy (DATA),28 and Investigation on the Duration of
Extended Adjuvant Letrozole (IDEAL)27 trials, no significant
improvement in disease-free or overall survival with ex-
tended endocrine therapywas observed. These data raise the
question of whether patients need to be specifically selected
for extended endocrine therapy (ie, basedonhigh risk for late
distant recurrence or high likelihood of benefit from ex-
tended therapy).
Strengths and Limitations
Strengths of our study include the mature clinical data with
clinical outcome and long-term follow-up, well-character-
ized tissue samples, and data on 6 prognostic signatures for
breast cancer. For all RNAanalyses, the sameextractionmeth-
ods for RNA were used. For all commercial signatures, stan-
dardized quantitative methods and analyses were used, and
all collaborators were blinded to clinical outcomes. Limita-
tions include that our results are only applicable for chemo-
therapy-free andpostmenopausalwomen.Anunintended se-
lection bias might have occurred because sample analyses
might have only been possible where sufficient amounts of
RNAwere available, but all assays yielded reportable results.
The IHC4, CTS, and in part the RSPC scorewere trained in the
TransATACcohort, and thus their performancemayhavebeen
overestimated inthisanalysis.Theriskgroupcutoffsof theROR
were defined in the TransATAC cohort for womenwith node-
negative and node-positive disease separately, therefore op-
timizing the cutoffs to identify a low-risk groupwith less than
10% risk and a high-risk groupwith greater than 20% risk. Fi-
nally, our current analysis was not able to assess the ability of
these signatures to predict the benefit from chemotherapy or
extended endocrine therapy.
Conclusions
Theprognostic signaturesevaluatedprovidedsignificant infor-
mation tohelpdetermineappropriate candidates consistingof
patients with ER-positive, ERBB2-negative breast cancer, for
whomchemotherapy and extended endocrine therapymight
not be indicated. In patients with node-negative disease, all
multigenesignaturesprovidedsignificantandclinicallymean-
ingfulprognostic informationbeyondclinical factors.Thecom-
binationof clinical andmolecular informationenhancedprog-
nosticperformance,particularly forwomenwithnode-positive
disease. All signatures performed similarly during the first 5
years of follow-up, butwe founddifferences during years 5 to
10,when these testsmaybevaluable fordecisionmakingwith
regard to extended endocrine treatment.
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